QTTB
Q32 Bio Inc.
Set alert
- YTD
- +168.37%
- 1 year
- +222.83%
- Open
- 8.87
- Prev close
- 8.87
- Mkt cap
- 265.25M
- Vol
- 268.18K
- Avg vol
- 713.73K
- EPS
- 3.15
- P/E
- 2.83
- Div yield
- 0.00%
More statistics
- Low
- 8.53
- High
- 8.98
- Forward P/E
- -0.60
- Beta
- 0.00
- Short ratio
- 6.74
- Inst. own
- 86.21%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 32.96
- 200-d avg
- 30.53
- 1y target
- 17.40
Key statistics
- Market cap
- 39.34M
- Enterprise value
- -23.25M
- Trailing P/E
- 0.00
- Forward P/E
- -0.60
- PEG ratio
- 0.00
- Price / sales
- -2.68
- Price / book
- 2.14
- EPS (TTM)
- -4.51
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- -14.66M
- Revenue growth
- 0.00%
- Free cash flow
- -71.27M
- Total cash
- 89.08M
- Total debt
- 22.10M
- Return on equity
- 0.00%
- Shares outstanding
- 12.18M
- Short % of float
- 0.00%
- 50-day average
- 32.96
- 200-day average
- 30.53
Analyst view
Consensus: buy
- Target (low)
- 9.00
- Target (mean)
- 17.40
- Target (high)
- 22.00
- Strong buy2
- Buy1
- Hold2
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -1.41 | -1.46 | -0.05 | -3.55% |
| Aug 8, 2024 | Jun 1, 2024 | -1.00 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -1.00 | -1.42 | -0.42 | -42.00% |
| May 9, 2024 | Mar 1, 2024 | -1.42 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -1.42 | -13.15 | -11.73 | -826.06% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 12, 2024 | BMO Capital | main | Outperform | Outperform |
| Dec 12, 2024 | Guggenheim | down | Buy | Neutral |
| Dec 11, 2024 | Oppenheimer | main | Outperform | Outperform |
| Dec 11, 2024 | Piper Sandler | main | Overweight | Overweight |
| Dec 11, 2024 | Wells Fargo | down | Overweight | Equal-Weight |
| Dec 11, 2024 | Leerink Partners | down | Outperform | Market Perform |
About Q32 Bio Inc.
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- q32bio.com
News
- Head to Head Contrast: Q32 Bio (NASDAQ:QTTB) & Applied Therapeutics (NASDAQ:APLT)
- Leerink Partners Initiates Coverage On Q32 Bio with Outperform Rating, Announces Price Target of $40
- Q32 Bio Announces Additional 36-Week Results And Initial Findings From The 16-Week Off-Drug Period From Part B Of The SIGNAL-AA Phase 2A Clinical Trial Evaluating Bempikibart In Patients With Severe Or Very Severe AA; Clinically Meaningful Efficacy Data Observed On Primary And Key Secondary Endpoints At Week 36; Robust Durability, Including Maintenance And Deepening Of Response
- Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026
- Jefferies Initiates Coverage On Q32 Bio with Buy Rating, Announces Price Target of $29
- Q32 Bio: Durable Hair Regrowth Remains The Goal
- Q32 Bio Presents Additional 36-Week Data From Its Part B Of SIGNAL-AA Phase 2a Clinical Study Of Bempikibart At European Academy Of Dermatology And Venereology Congress
- Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026
- Q32 Bio Inc. (QTTB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D.
Your note
Sign in to keep a note on QTTB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALLOWAY PAUL | President | Conversion of Exercise of derivative security | Mar 24, 2024 | 51,566 |
| BLUM MICHAEL LEE | Officer | Sale | Jan 8, 2023 | 9,408 |
| JORDAN JULIE | Officer | Conversion of Exercise of derivative security | Aug 2, 2023 | 7,496 |
| MICHAUD CHARLES JR. | Officer and Treasurer | Conversion of Exercise of derivative security | Mar 24, 2024 | 18,046 |
| SEYMOUR ALBERT B | Chief Executive Officer | Conversion of Exercise of derivative security | Sep 5, 2023 | 150,874 |
| SMITH W BRADFORD | Chief Financial Officer | Sale | Jan 8, 2023 | 14,219 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Orbimed Advisors LLC. | 18.50% | 2,252,987 | 7.28M | Sep 29, 2024 |
| Atlas Venture Life Science Advisors, LLC | 17.18% | 2,092,106 | 6.76M | Sep 29, 2024 |
| Carlyle Group Inc. | 9.05% | 1,102,741 | 3.56M | Sep 29, 2024 |
| FMR, LLC | 3.50% | 426,302 | 1.38M | Sep 29, 2024 |
| Blackrock Inc. | 3.35% | 408,659 | 1.32M | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 3.32% | 404,411 | 1.31M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Select Portfolios - Biotechnology | 2.13% | 259,900 | 839.48K | Oct 30, 2024 |
| Fidelity Advisor Biotechnology Fund | 1.66% | 201,678 | 651.42K | Oct 30, 2024 |
| Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund | 1.56% | 190,000 | 613.70K | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 1.34% | 162,796 | 525.83K | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.28% | 155,361 | 501.82K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.63% | 76,718 | 247.80K | Sep 29, 2024 |